靶向EGFR和HER3的双特异性抗体偶联药物BL-B01D1治疗转移性食管鳞状细胞癌:一项1b期试验
本研究为BL-B01D1在82例经治晚期食管鳞状细胞癌患者中的1b期试验,主要终点为推荐2期剂量。2.5 mg/kg组确认客观缓解率为39.6%,疾病控制率为79.2%;2.0 mg/kg组分别为15.0%和50.0%。2期剂量确定为2.5 mg/kg D1D8每3周一次,≥3级治疗相关不良事件发生率为63.3%。
要点
- BL-B01D1在经治转移性食管鳞癌中显示出令人鼓舞的疗效,2.5 mg/kg组确认客观缓解率为39.6%。
- 2期推荐剂量为2.5 mg/kg D1D8每3周一次,该剂量下≥3级治疗相关不良事件发生率为63.3%。
- 常见不良事件包括贫血(28.3%)、白细胞减少和血小板减少(各18.3%)、中性粒细胞减少(16.7%),观察到2例≥3级间质性肺病。
核心结论
- BL-B01D1在转移性食管鳞状细胞癌患者中显示出令人鼓舞的疗效和可控的安全性。
- 一项进一步的3期临床试验已经启动。
研究设计与样本
- 研究为BL-B01D1的1b期试验,纳入82例既往接受过治疗的食管鳞状细胞癌患者。
- 主要终点为推荐2期剂量。
- 给药剂量为2.0 mg/kg(n=22)和2.5 mg/kg(n=60),D1D8静脉输注,每3周一次。
主要发现
- 全部82例患者的确认客观缓解率为29.3%(24/82),可评估患者(73例)中为32.9%(24/73)。
- 2.5 mg/kg组确认客观缓解率为39.6%(21/53),疾病控制率为79.2%(42/53)。
- 2.0 mg/kg组确认客观缓解率为15.0%(3/20),疾病控制率为50.0%(10/20)。
- 2.5 mg/kg组≥3级治疗相关不良事件发生率为63.3%;最常见不良事件为贫血(28.3%)、白细胞减少和血小板减少(各18.3%)、中性粒细胞减少(16.7%)。
- 观察到2例≥3级间质性肺病。
关键数值与推荐
- 2期推荐剂量确定为2.5 mg/kg D1D8每3周一次。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Research on patients with advanced esophageal squamous cell carcinoma (ESCC) who have progressed on immunotherapy remains limited. BL-B01D1 is a first-in-class antibody-drug conjugate consisting of an EGFR-HER3 bispecific antibody bound to a topoisomerase I inhibitor (Ed-04) payload via a cleavable linker. Here, we present safety and efficacy data from a phase 1 study of BL-B01D1, in 82 patients previously treated for ESCC. The primary endpoint was the recommended phase 2 dose. Administered doses were 2.0 (n = 22) and 2.5 (n = 60) mg kg-1 D1D8 infusion every 3 weeks (Q3W). The confirmed objective response rate (cORR) was 29.3% (24 of 82) in all patients and 32.9% (24 of 73) among evaluable patients. For patients dosed at 2.5 mg kg-1, cORR was 39.6% (21 of 53) and disease control rate was 79.2% (42 of 53). In the 2.0 mg kg-1 group, cORR was 15.0% (3 of 20), and the disease control rate was 50.0% (10 of 20). The phase 2 dose was established at 2.5 mg kg-1 D1D8 Q3W. The incidence of G3 treatment-related adverse events at 2.5 mg kg-1 was 63.3%; most common adverse events were anemia (28.3%), leukopenia and thrombocytopenia (18.3%, each), and neutropenia (16.7%). Two cases of ≥G3 interstitial lung disease were observed. Overall, BL-B01D1 demonstrated promising efficacy and manageable safety in patients with metastatic ESCC. A further phase 3 clinical trial has already been initiated. ClinicalTrials.gov registration: NCT05262491 .
引用
- Liu C, Liu D, Ji Y, et al. A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial. Nat Med. 2025. PMID: 40640393. doi:10.1038/s41591-025-03792-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。